NCT00284154

Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer

A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer. The purpose of this research trial is to study the effectiveness of vinflunine in patients with relapsed extensive small cell lung cancer, evaluate the toxicity, and evaluate how long the response to this drug lasts.

Detailed description

Eligible patients will receive vinflunine as a 15-20 minute intravenous (IV)infusion once every three weeks (21 days). This three week treatment period is called a cycle. Patients whose cancer has not grown or if it has decreased in size may receive up to 6 cycles of vinflunine. Evaluation will be conducted every other cycle.

Conditions

• Carcinoma, Small Cell
• Lung Cancer

Interventions

Type	Name	Description
DRUG	Vinflunine	320mg/m2 every 21 days as a 15-20 minute infusion

Timeline

• Start date: 2006-01-01
• Primary completion: 2009-05-01
• Completion: 2009-11-01
• First posted: 2006-01-31
• Last updated: 2013-03-13
• Results posted: 2013-03-13

Locations

3 sites across 1 country: United States